A $226B Copper Spending Jackpot
On November 15, 2021, President Biden signed the biggest infrastructure spending bill of all time. A staggering $226 BILLION is earmarked for projects requiring huge amounts of copper. Turns out, copper is a desperately needed mineral to power the green revolution of clean, renewable energy.
See Who Can Benefit From this Initiative
Rafael Amado, insider at Allogene Therapeutics

Rafael Amado Insider Information

Rafael G. Amado, MD, is the Executive Vice President of Research and Development and Chief Medical Officer of Allogene. Rafael has over 15 years of biotechnology and pharmaceutical industry experience leading clinical and research teams. He most recently served as President of R&D, after serving as Chief Medical Officer, at Adaptimmune. Previously, he held several roles of increasing responsibility at GSK, most recently as Senior Vice President and Head of Oncology R&D. Prior to GSK, Rafael served as Executive Director of Therapeutic Oncology at Amgen, where he was responsible for worldwide clinical research strategy and execution and oversaw development activities for several investigational agents for molecularly characterized tumors. Before joining Amgen, he was on the faculty at the University of California, Los Angeles, most recently serving as Assistant Clinical Professor, Department of Medicine, Division of Hematology/Oncology. Rafael received an MD from the University of Seville School of Medicine and completed his internship and residency in internal medicine at Michael Reese Hospital and Medical Center, a University of Chicago-affiliated hospital. He completed a fellowship in hematology/oncology at the University of California, Los Angeles.

What is Rafael Amado's net worth?

The estimated net worth of Rafael Amado is at least $6.20 million as of June 21st, 2022. Dr. Amado owns 544,257 shares of Allogene Therapeutics stock worth more than $6,204,530 as of June 30th. This net worth approximation does not reflect any other investments that Dr. Amado may own. Additionally, Dr. Amado receives an annual salary of $910,720.00 as CMO at Allogene Therapeutics. Learn More about Rafael Amado's net worth.

How old is Rafael Amado?

Dr. Amado is currently 58 years old. There are 7 older executives and no younger executives at Allogene Therapeutics. The oldest executive at Allogene Therapeutics is Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D., Co-Founder & Exec. Chairman, who is 73 years old. Learn More on Rafael Amado's age.

What is Rafael Amado's salary?

As the CMO of Allogene Therapeutics, Inc., Dr. Amado earned a total compensation package of $2,663,819.00 in 2020. Dr. Amado earned a salary of $510,000.00, a bonus of $75,000.00, stock awards of $561,176.00, options awards of $1,262,643.00, non-equity compensation of $255,000.00, and no other miscellaneous compensation. The highest earning executive at Allogene Therapeutics is Dr. David D. Chang M.D., Ph.D., Co-Founder, Pres, CEO & Director, who commands a salary of $1,090,000.00 per year. Learn More on Rafael Amado's salary.

How do I contact Rafael Amado?

The corporate mailing address for Dr. Amado and other Allogene Therapeutics executives is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Allogene Therapeutics can also be reached via phone at (650) 457-2700 and via email at [email protected] Learn More on Rafael Amado's contact information.

Has Rafael Amado been buying or selling shares of Allogene Therapeutics?

In the last ninety days, Rafael Amado has sold $107,460.00 of Allogene Therapeutics stock. 0 shares of the firm's stock in a transaction on Thursday, June 30th. Learn More on Rafael Amado's trading history.

Who are Allogene Therapeutics' active insiders?

Allogene Therapeutics' insider roster includes Rafael Amado (CMO), Arie Belldegrun (Director), Veer Bhavnagri (General Counsel), and Owen Witte (Director). Learn More on Allogene Therapeutics' active insiders.

Are insiders buying or selling shares of Allogene Therapeutics?

During the last year, Allogene Therapeutics insiders bought shares 1 times. They purchased a total of 155,039 shares worth more than $1,953,491.40. During the last year, insiders at the sold shares 13 times. They sold a total of 117,840 shares worth more than $1,523,000.17. The most recent insider tranaction occured on June, 22nd when Director Owen N Witte sold 10,000 shares worth more than $117,600.00. Insiders at Allogene Therapeutics own 26.3 % of the company. Learn More about insider trades at Allogene Therapeutics.

Information on this page was last updated on 6/22/2022.

Rafael Amado Insider Trading History at Allogene Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/21/2022Sell2,000$11.18$22,360.00544,257View SEC Filing Icon  
5/19/2022Sell11,500$7.40$85,100.00546,257View SEC Filing Icon  
3/15/2022Sell5,169$7.71$39,852.99View SEC Filing Icon  
10/1/2021Sell11,507$24.35$280,195.45View SEC Filing Icon  
10/7/2020Sell16,538$39.40$651,597.20111,677View SEC Filing Icon  
See Full Table

Rafael Amado Buying and Selling Activity at Allogene Therapeutics

This chart shows Rafael Amado's buying and selling at Allogene Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Allogene Therapeutics Company Overview

Allogene Therapeutics logo
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $11.40
Low: $11.15
High: $11.65

50 Day Range

MA: $8.88
Low: $6.78
High: $12.28

2 Week Range

Now: $11.40
Low: $6.43
High: $27.86

Volume

30,527 shs

Average Volume

1,922,816 shs

Market Capitalization

$1.64 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.